Theravance Biopharma Gross Profit

Theravance Biopharma (TBPH) currently reports a gross profit of $33M as of June 2026. That compares with $62M in the prior-year period — down 47.2% year over year. That is below the Healthcare sector average of $65B. Use the charts on this page to explore Theravance Biopharma's gross profit history and peer comparisons.

Theravance Biopharma's gross profit decreased from $62M to $33M — a 47.2% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Theravance Biopharma's gross profit of $33M is lower than the Healthcare sector average of $65B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Theravance Biopharma reported $33M in gross profit as of June 2026. That compares with $62M in the prior-year period — down 47.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current gross profit of $33M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $65B. From there, open related valuation or income-statement pages for Theravance Biopharma, and consider following TBPH for alerts when major investors trade the stock.